Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1995 Nov;116(6):2673–2678. doi: 10.1111/j.1476-5381.1995.tb17225.x

Functional characterization of receptors with affinity for PYY, NPY, [Leu31,Pro34]NPY and PP in a human colonic epithelial cell line.

H M Cox 1, I R Tough 1
PMCID: PMC1909132  PMID: 8590988

Abstract

1. Confluent epithelial layers of a human adenocarcinoma cell line called Colony-6 have been shown to respond to nanomolar concentrations of vasoactive intestinal polypeptide (VIP), peptide YY (PYY), neuropeptide Y (NPY) and somatostatin (Som). 2. The VIP-induced increase in basal short-circuit current (SCC) was attenuated by basolateral application of Som, PYY or NPY, and also by the Y1-receptor agonist [Leu31,Pro34]NPY, as well as pancreatic polypeptide (PP). High concentrations (0.1-3.0 microM) of NPY(2-36) were effective but the C-terminal fragment NPY(13-36) (0.1-1.0 microM) and desamidoNPY (0.6 microM) were not active. A rank order of agonist EC50 values was: PYY > NPY > [Leu31,Pro34]NPY > PP > NPY(2-36) >> NPY (13-36). 3. Receptors for all these peptides were preferentially located within the basolateral domain. Apical addition of PP (1 microM) and Som (100 nM) had no effect upon basal SCC while apical VIP (10 nM) responses were 18%, and apical PYY (100 nM) were 27% the size of respective basolateral controls (100%). 4. Cross-desensitization was observed between [Leu31,Pro34]NPY (1 microM) and both PYY (100 nM) and PP (1 microM) and between PYY and NPY(2-36) (1 microM), but was not significant between PYY (100 nM) and PP (1 microM). We suggest that either these cells express a single new Y-receptor with an unusual phenotype or that two Y-receptor populations exist in Colony-6 cells.

Full text

PDF
2673

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ballantyne G. H., Goldenring J. R., Fleming F. X., Rush S., Flint J. S., Fielding L. P., Binder H. J., Modlin I. M. Inhibition of VIP-stimulated ion transport by a novel Y-receptor phenotype in rabbit distal colon. Am J Physiol. 1993 May;264(5 Pt 1):G848–G854. doi: 10.1152/ajpgi.1993.264.5.G848. [DOI] [PubMed] [Google Scholar]
  2. Bilchik A. J., Hines O. J., Adrian T. E., McFadden D. W., Berger J. J., Zinner M. J., Ashley S. W. Peptide YY is a physiological regulator of water and electrolyte absorption in the canine small bowel in vivo. Gastroenterology. 1993 Nov;105(5):1441–1448. doi: 10.1016/0016-5085(93)90149-7. [DOI] [PubMed] [Google Scholar]
  3. Cox H. M., Cuthbert A. W., Håkanson R., Wahlestedt C. The effect of neuropeptide Y and peptide YY on electrogenic ion transport in rat intestinal epithelia. J Physiol. 1988 Apr;398:65–80. doi: 10.1113/jphysiol.1988.sp017029. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Cox H. M., Cuthbert A. W. Neuropeptide Y antagonises secretagogue evoked chloride transport in rat jejunal epithelium. Pflugers Arch. 1988 Nov;413(1):38–42. doi: 10.1007/BF00581226. [DOI] [PubMed] [Google Scholar]
  5. Cox H. M., Cuthbert A. W. The effects of neuropeptide Y and its fragments upon basal and electrically stimulated ion secretion in rat jejunum mucosa. Br J Pharmacol. 1990 Oct;101(2):247–252. doi: 10.1111/j.1476-5381.1990.tb12695.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Cox H. M., Krstenansky J. L. The effects of selective amino acid substitution upon neuropeptide Y antisecretory potency in rat jejunum mucosa. Peptides. 1991 Mar-Apr;12(2):323–327. doi: 10.1016/0196-9781(91)90020-p. [DOI] [PubMed] [Google Scholar]
  7. Cox H. M., Tough I. R. Calcitonin gene-related peptide receptors in human gastrointestinal epithelia. Br J Pharmacol. 1994 Dec;113(4):1243–1248. doi: 10.1111/j.1476-5381.1994.tb17131.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Edwards R. M. Neuropeptide Y inhibits cAMP accumulation in renal proximal convoluted tubules. Regul Pept. 1990 Oct 8;30(3):201–206. doi: 10.1016/0167-0115(90)90095-e. [DOI] [PubMed] [Google Scholar]
  9. Ferrar J. A., Cuthbert A. W., Cox H. M. The antisecretory effects of somatostatin and analogues in rat descending colon mucosa. Eur J Pharmacol. 1990 Aug 10;184(2-3):295–303. doi: 10.1016/0014-2999(90)90621-c. [DOI] [PubMed] [Google Scholar]
  10. Foucart S., Bleakman D., Bindokas V. P., Miller R. J. Neuropeptide Y and pancreatic polypeptide reduce calcium currents in acutely dissociated neurons from adult rat superior cervical ganglia. J Pharmacol Exp Ther. 1993 May;265(2):903–909. [PubMed] [Google Scholar]
  11. Gilbert W. R., Frank B. H., Gavin J. R., 3rd, Gingerich R. L. Characterization of specific pancreatic polypeptide receptors on basolateral membranes of the canine small intestine. Proc Natl Acad Sci U S A. 1988 Jul;85(13):4745–4749. doi: 10.1073/pnas.85.13.4745. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Grundemar L., Håkanson R. Neuropeptide Y effector systems: perspectives for drug development. Trends Pharmacol Sci. 1994 May;15(5):153–159. doi: 10.1016/0165-6147(94)90076-0. [DOI] [PubMed] [Google Scholar]
  13. Holzer-Petsche U., Petritsch W., Hinterleitner T., Eherer A., Sperk G., Krejs G. J. Effect of neuropeptide Y on jejunal water and ion transport in humans. Gastroenterology. 1991 Aug;101(2):325–330. doi: 10.1016/0016-5085(91)90007-8. [DOI] [PubMed] [Google Scholar]
  14. Hubel K. A., Renquist K. S. Effect of neuropeptide Y on ion transport by the rabbit ileum. J Pharmacol Exp Ther. 1986 Jul;238(1):167–169. [PubMed] [Google Scholar]
  15. Inui A., Sano K., Miura M., Hirosue Y., Nakajima M., Okita M., Baba S., Kasuga M. Evidence for further heterogeneity of the receptors for neuropeptide-Y and peptide-YY in tumor cell lines derived from neural crest. Endocrinology. 1992 Nov;131(5):2090–2096. doi: 10.1210/endo.131.5.1330489. [DOI] [PubMed] [Google Scholar]
  16. Krause J., Eva C., Seeburg P. H., Sprengel R. Neuropeptide Y1 subtype pharmacology of a recombinantly expressed neuropeptide receptor. Mol Pharmacol. 1992 May;41(5):817–821. [PubMed] [Google Scholar]
  17. MacVinish L. J., Pickles R. J., Cuthbert A. W. Cyclic AMP and Ca2+ interactions affecting epithelial chloride secretion in human cultured colonic epithelia. Br J Pharmacol. 1993 Feb;108(2):462–468. doi: 10.1111/j.1476-5381.1993.tb12826.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Marsh K. A., Stamp G. W., Kirkland S. C. Isolation and characterization of multiple cell types from a single human colonic carcinoma: tumourigenicity of these cell types in a xenograft system. J Pathol. 1993 Aug;170(4):441–450. doi: 10.1002/path.1711700407. [DOI] [PubMed] [Google Scholar]
  19. Medeiros M. D., Turner A. J. Processing and metabolism of peptide-YY: pivotal roles of dipeptidylpeptidase-IV, aminopeptidase-P, and endopeptidase-24.11. Endocrinology. 1994 May;134(5):2088–2094. doi: 10.1210/endo.134.5.7908871. [DOI] [PubMed] [Google Scholar]
  20. Mentlein R., Dahms P., Grandt D., Krüger R. Proteolytic processing of neuropeptide Y and peptide YY by dipeptidyl peptidase IV. Regul Pept. 1993 Dec 10;49(2):133–144. doi: 10.1016/0167-0115(93)90435-b. [DOI] [PubMed] [Google Scholar]
  21. Michel M. C., Gaida W., Beck-Sickinger A. G., Wieland H. A., Doods H., Dürr H., Jung G., Schnorrenberg G. Further characterization of neuropeptide Y receptor subtypes using centrally truncated analogs of neuropeptide Y: evidence for subtype-differentiating effects on affinity and intrinsic efficacy. Mol Pharmacol. 1992 Oct;42(4):642–648. [PubMed] [Google Scholar]
  22. Michel M. C. Receptors for neuropeptide Y: multiple subtypes and multiple second messengers. Trends Pharmacol Sci. 1991 Oct;12(10):389–394. doi: 10.1016/0165-6147(91)90610-5. [DOI] [PubMed] [Google Scholar]
  23. Penner S. B., Smyth D. D., Glavin G. B. Effects of neuropeptide Y and [Leu31,Pro34] neuropeptide Y on experimental gastric lesion formation and gastric secretion in the rat. J Pharmacol Exp Ther. 1993 Jul;266(1):339–343. [PubMed] [Google Scholar]
  24. Playford R. J., Domin J., Beacham J., Parmar K. B., Tatemoto K., Bloom S. R., Calam J. Preliminary report: role of peptide YY in defence against diarrhoea. Lancet. 1990 Jun 30;335(8705):1555–1557. doi: 10.1016/0140-6736(90)91378-n. [DOI] [PubMed] [Google Scholar]
  25. Saria A., Beubler E. Neuropeptide Y (NPY) and peptide YY (PYY) inhibit prostaglandin E2-induced intestinal fluid and electrolyte secretion in the rat jejunum in vivo. Eur J Pharmacol. 1985 Dec 10;119(1-2):47–52. doi: 10.1016/0014-2999(85)90320-6. [DOI] [PubMed] [Google Scholar]
  26. Schwartz T. W., Sheikh S. P., O'Hare M. M. Receptors on phaeochromocytoma cells for two members of the PP-fold family--NPY and PP. FEBS Lett. 1987 Dec 10;225(1-2):209–214. doi: 10.1016/0014-5793(87)81159-6. [DOI] [PubMed] [Google Scholar]
  27. Servin A. L., Rouyer-Fessard C., Balasubramaniam A., Saint Pierre S., Laburthe M. Peptide-YY and neuropeptide-Y inhibit vasoactive intestinal peptide-stimulated adenosine 3',5'-monophosphate production in rat small intestine: structural requirements of peptides for interacting with peptide-YY-preferring receptors. Endocrinology. 1989 Feb;124(2):692–700. doi: 10.1210/endo-124-2-692. [DOI] [PubMed] [Google Scholar]
  28. Sheikh S. P., Sheikh M. I., Schwartz T. W. Y2-type receptors for peptide YY on renal proximal tubular cells in the rabbit. Am J Physiol. 1989 Dec;257(6 Pt 2):F978–F984. doi: 10.1152/ajprenal.1989.257.6.F978. [DOI] [PubMed] [Google Scholar]
  29. van Valen F., Winkelmann W., Jürgens H. Expression of functional Y1 receptors for neuropeptide Y in human Ewing's sarcoma cell lines. J Cancer Res Clin Oncol. 1992;118(7):529–536. doi: 10.1007/BF01225268. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES